Third Circuit Allows Spector Partners to Proceed with Effexor claims

The Third Circuit Court of Appeals has just reversed dismissal of antitrust claims against Pfizer and Teva over the blood thinner Aggranox and its generic equivalents. Spector Partners is co-lead counsel in the case, alleging that Pfizer took anti-competitive actions to avoid competition for Effexor. These illegal acts included making false claims to the Patent and Trademark Office and entering into anti-competitive reverse payment settlement with a major generic manufacturer, Teva. The District Court dismissed certain claims in Spector Partners’ complaint, however the Third Circuit found that the Plaintiffs’ allegations were plausible and reversed the dismissal. Spector Partners and its co-lead counsel look forward to pursuing Teva and Pfizer for the hundreds of millions of dollars in overcharges caused by their anti-competitive conduct.